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ABSTRACT
Introduction: This study evaluated the effects of an antagonistic analog of 
growth hormone-releasing hormone, MIA-602, on tumor growth, response to 
doxorubicin, expression of drug resistance genes, and efflux pump function in human 
triple negative breast cancers. 
Methods: HCC1806 (doxorubicin-sensitive) and MX-1 (doxorubicin-resistant), 
cell lines were xenografted into nude mice and treated with MIA-602, doxorubicin, or 
their combination. Tumors were evaluated for changes in volume and the expression 
of the drug resistance genes MDR1 and NANOG. In-vitro cell culture assays were used 
to analyze the effect of MIA-602 on efflux pump function. 
Results: Therapy with MIA-602 significantly reduced tumor growth and enhanced 
the efficacy of doxorubicin in both cell lines. Control HCC1806 tumors grew by 435%, 
while the volume of tumors treated with MIA-602 enlarged by 172.2% and with 
doxorubicin by 201.6%. Treatment with the combination of MIA-602 and doxorubicin 
resulted in an increase in volume of only 76.2%. Control MX-1 tumors grew by 907%, 
while tumors treated with MIA-602 enlarged by 434.8% and with doxorubicin by 
815%. The combination of MIA-602 and doxorubicin reduced the increase in tumor 
volume to 256%. Treatment with MIA-602 lowered the level of growth hormone-
releasing hormone and growth hormone-releasing hormone receptors and significantly 
reduced the expression of multidrug resistance (MDR1) gene and the drug resistance 
regulator NANOG. MIA-602 also suppressed efflux pump function in both cell lines. 
Conclusions: We conclude that treatment of triple negative breast cancers 
with growth hormone-releasing hormone antagonists reduces tumor growth and 
potentiates the effects of cytotoxic therapy by nullifying drug resistance. 
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INTRODUCTION 
In the United States alone, nearly 200,000 women 
are afflicted with breast cancer each year and 41,000 
die as a result of their malignancy.[1] Breast cancer is 
the leading cause of mortality in Hispanic and African-
American women and the second most common cause 
of cancer-related death of women. The US figures can be 
extrapolated to approximately 4 million new cases and 
820,000 deaths per year, worldwide. 
Breast cancer is a very heterogeneous disease. The 
subtype defined as triple negative breast cancer (TNBC) is 
negative for estrogen receptor, progesterone receptor, and 
the human epidermal growth factor receptor 2 (Her2).[2] 
TNBC accounts for 10-15% of all breast cancer cases and 
has a higher rate of mortality than other malignancies. The 
TNBC phenotype is hereditary, affects younger women, is 
more invasive, and has a much poorer prognosis.[3] These 
cancers are extremely resistant to the treatment options 
available for other breast cancers, with drug efflux being 
the primary mechanism of resistance.[4] This accounts for 
the low survival rate of women with TNBC.[5] Alternate 
treatment strategies must therefore be devised to address 
this clinical deficiency.
Growth hormone releasing hormone (GHRH) is a 
neuropeptide hormone, secreted by the hypothalamus, 
which regulates the synthesis and release of growth 
hormone by the pituitary.[6] Growth hormone 
subsequently stimulates the release of hepatic insulin-
like growth factor, which is a major anabolic growth 
factor and a potent mitogen for many neoplasms.[7-9] 
Additionally, GHRH and GHRH receptors (GHRH-R) are 
not confined to the hypothalamic–pituitary axis, but are 
also produced by various extra-hypothalamic sites.[10-16] 
Biologically active GHRH, mRNA for GHRH, GHRH-R, 
and splice variants of GHRH-R have been identified in 
surgical specimens and tumor cell lines of a multitude of 
human cancers, including various types of breast cancer.
[17-28] Much evidence indicates that GHRH acts as an 
autocrine/paracrine growth factor in many human cancers 
[6, 23, 29-31] including that of the breast.[32] Pituitary-
type GHRH-R and splice variant 1 of GHRH-R appear 
to mediate the direct effects of GHRH and its analogs on 
tumors.[33] In vitro and in vivo proliferation of various 
human cancers is suppressed by antagonistic analogs of 
GHRH (referred to as “GHRH antagonists”).[8, 34, 35] 
These findings support the concept of GHRH as a growth 
factor for tumors and suggest that GHRH-R could be used 
as a suitable therapeutic target. 
We have recently reported that the GHRH 
antagonist, MIA-602, suppresses the expression of 
inflammatory cytokines in human TNBC tumors 
xenografted into nude mice.[36] Cytokines have been 
shown to play a major role in the cellular signaling 
involved in the pathogenesis of breast cancer.[37-39] In 
this study, we used HCC1806 and doxorubicin-resistant 
MX-1 human TNBC cell lines xenografted into nude mice 
to evaluate the effects of a GHRH antagonist (MIA-602) 
alone and in combination with doxorubicin. We examined 
the effects of treatment on tumor growth, drug resistance, 
GHRH-R levels, expression of MDR1 and Nanog, and 
efflux pump activity.
RESULTS
Effect of treatment with MIA-602, doxorubicin, 
or their combination on the growth of xenografts 
of HCC1806 and MX-1 human TNBC
Treatment of nude mice bearing human TNBC 
tumors was initiated after the tumors had reached a 
volume of ~100 mm3 and lasted for five weeks. Control 
HCC1806 tumors grew by 435.3% (±41.6%) of the 
initial tumor volume by week five, while tumors treated 
with MIA-602 augmented by only 172.2% (±15.1%), 
significantly (P < 0.001) less than controls. Tumor volume 
of mice given doxorubicin increased by 201.6% (±7.1%) 
and was also significantly (P < 0.001) reduced compared 
to controls. Thus, treatment with MIA-602 reduced the 
growth of HCC1806 tumors by 60% and doxorubicin by 
54% compared to controls. The combination of MIA-602 
and doxorubicin had the greatest inhibitory effect and 
diminished the growth of HCC1806 tumors by 83% versus 
controls. The treatment with the combination of MIA-602 
and doxorubicin resulted in the smallest increase in tumor 
Figure 1: A. HCC1806 tumors responded significantly better 
to combination treatment than to either MIA-602 or doxorubicin 
alone. B. Treatment of MX-1 tumors (doxorubicin resistant) 
with doxorubicin/MIA-602 combination resulted in elimination 
of resistance to doxorubicin. Vertical bars indicate ± SEM. * 
Combination vs. control (P < 0.001), MIA-602 (P < 0.05), and 
doxorubicin (P < 0.001). N= 16 tumors.
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volume of 76.2% (±13.6%). The growth of tumors treated 
with the combination was significantly smaller than that of 
controls (P < 0.001) and tumors treated with either MIA-
602 (P < 0.05) or doxorubicin (P < 0.001) (figure 1a).
Control MX-1 tumors grew by 907.4% 
(±37.4%) of the initial tumor volume by week five, 
but those treated with MIA-602 increased by 434.8% 
(±12.9%); significantly (P < 0.001) less than controls. 
Not surprisingly, the growth of tumors treated with 
doxorubicin, which attained a volume 814.9% (±34.7%) 
of the initial size, was not significantly different than 
controls. Treatment with the combination of MIA-602 and 
doxorubicin led to an increase in final tumor volume of 
only 256.0% (±10.3%). Treatment with MIA-602 reduced 
the growth of MX-1 tumors by 52% and doxorubicin by 
only 10% compared to controls. The combination of MIA-
602 and doxorubicin decreased growth of MX-1 tumors 
by 72%. Combination therapy resulted in significantly 
reduced growth compared to controls (P < 0.001), and 
tumors treated with MIA-602 (P < 0.05) or doxorubicin (P 
< 0.001) (figure 1b).
Expression of GHRH and GHRH-R genes by 
xenografts of HCC1806 and MX-1 human TNBC
Protein and mRNA for GHRH and GHRH-R were 
expressed in both HCC1806 and MX-1 human TNBC 
cell lines as determined after five weeks of treatment 
using qRT-PCR. The expression of GHRH and GHRH-R 
genes by HCC1806 tumors was significantly (P < 
0.05) suppressed by treatment, in-vivo, with MIA-602. 
HCC1806 tumors treated with the GHRH antagonist for 
five weeks expressed 91.8% (±3.8%) less GHRH and 
the levels of GHRH-R were 59.4% (±5.7%) lower than 
in controls. Expression of GHRH and GHRH-R genes by 
MX-1 tumors was also significantly (P < 0.05) reduced 
by therapy with MIA-602. MX-1 tumors treated with 
the GHRH antagonist for five weeks expressed 56.2% 
(±5.2%) less GHRH and 56.1% (±14.9%) less GHRH-R 
than controls (figure 2). 
Expression of regulatory genes of drug resistance 
by xenografts of HCC1806 and MX-1 human 
TNBC
The expression of the tumoral multidrug resistance 
gene (MDR1), which encodes P-glycoprotein, and 
NANOG, a stem-cell marker and a regulator of the 
expression of drug resistance genes, was determined using 
qRT-PCR. 
In-vivo treatment of HCC1806 tumors with MIA-
602, doxorubicin, or combination resulted in significant 
(P < 0.01) suppression of MDR1 and NANOG gene 
expression relative to controls. The expression of MDR1 
in tumors treated with combination was more powerfully 
suppressed than with either compound alone (P < 0.001). 
Analysis of NANOG indicates that the combination 
treatment suppresses expression significantly (P < 0.001) 
more than either compound alone (figure 3a). Therapy 
of doxorubicin resistant MX-1 tumors with MIA-602 
or combination led to significant (P < 0.05) reduction in 
MDR1 and NANOG gene expression relative to controls. 
The combination also significantly (P < 0.05) suppressed 
the expression of MDR1 and NANOG genes compared to 
doxorubicin alone, which did not have a significant effect 
(figure 3b). 
Figure 2: Treatment of HCC1806 and MX-1 human 
TNBC tumors with the GHRH antagonist MIA-602 
significantly suppressed the expression of GHRH and 
GHRH-R genes. Vertical bars indicate ± SEM, n=12 tumors, 
* P < 0.01 vs. control.
Figure 3: Expression of both NANOG and MDR1 was 
significantly suppressed by treatment with the MIA-
602/doxorubicin combination compared to MIA-602 
or doxorubicin alone in A. HCC1806 and doxorubicin alone 
in B. doxorubicin resistant MX-1. Vertical bars indicate ± SEM, 
n=12 tumors, * P < 0.01 vs. control.
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Lowering of efflux pump activity in HCC1806 and 
MX-1 human TNBC cells
Efflux pump function was determined using a 
fluorescent dye (Calcein AM) retention assay. [40] The 
cells were treated with 5µM GHRH antagonist, MIA-
602, for 4 hours and retention of Calcein was determined. 
HCC1086 cells and MX-1 cells, treated with 5 µM 
MIA-602, retained 7% and 40% more dye than controls, 
respectively. Both reductions in efflux pump function were 
significant compared to the respective controls (P < 0.01) 
(figure 4).
DISCUSSION
Much information has now been accumulated 
concerning the role of GHRH, GHRH receptors, and 
receptor splice variants (SV) in carcinogenesis. The 
proliferation of various human cancers in vitro is 
suppressed by GHRH antagonists.[41] A report suggests 
that the dysregulation of GHRH expression or autocrine/
paracrine secretion contributes to the pathogenesis of 
breast and other cancers.[42] In vivo investiagtions 
have demonstrated the anti-tumor activity of GHRH 
antagonists against multiple cancer types. Studies on the 
effects of GHRH antagonists on prostate and lung cancers 
demonstrated their ability to modulate signaling pathways 
involved in cellular proliferation, survival, metastasis, and 
apoptosis.[43-45] 
Increased expression of inflammatory cytokines 
correlates with higher tumor grade, greater metastatic 
potential, and higher incidence of resistance to treatment, 
all of which predict a poorer survival.[46] Among the roles 
of cytokines in breast cancer is their ability to regulate 
epithelial-mesenchymal transitions (EMT) and drug 
resistance.[38, 47, 48] In the course of EMT, expression 
of intercellular adhesion molecules, among other 
characteristics of an epithelial phenotype, is lost and cells 
acquire a stem-cell-like or “mesenchymal” phenotype. 
The resulting phenotype is highly motile and possesses 
stem-cell-like properties, a high degree of resistance to 
treatments, and an increased rate of drug efflux.[49-51]
Numerous studies have firmly established the 
regulatory role of inflammatory cytokines in cancer.[3, 
37-39, 46, 47, 50, 52] Our group has recently reported the 
reduction in prostate size and suppression of inflammatory 
cytokines by GHRH antagonists in a rodent model of 
experimental benign prostatic hyperplasia (BPH).[53] 
We have also demonstrated similar effects of GHRH 
antagonists on in vivo cytokine gene expression by 
HCC1806 and MX-1 triple negative human breast cancer. 
Analysis of the genes expressed by tumors treated with 
MIA-602 indicates that it suppresses the expression of 
tumoral inflammatory cytokines.[36] 
Studies on human cancer lines xenografted into 
nude mice have demonstrated anti-tumor activity of 
GHRH antagonists against multiple human cancer types.
[6, 30, 54] Evaluations of GHRH antagonists in prostate 
and lung cancers demonstrated their ability to modulate 
signaling pathways involved in cellular proliferation, 
survival, metastasis, and apoptosis.[23, 43, 44, 55] 
Among the affected pathways is the PI3K-AKT, which 
regulates inflammatory cytokines through NF-κβ.[43, 44, 
56] Activation of the NF-κβ pathway by inflammatory 
cytokines has also been shown to enhance drug resistance 
in breast cancer. Analyses indicate that treatment with 
GHRH antagonists suppresses the expression of pro-
inflammatory cytokines in BPH.[13, 53] 
Cell lines used in this study (HCC1806 and MX-
1) were both susceptible to treatment with the GHRH 
antagonist, MIA-602. Tumors treated with MIA-602 
showed a significant reduction in growth compared to 
controls. Combination of the GHRH antagonist with 
doxorubicin increased this inhibition of growth. Most 
importantly, MX-1 tumors, which are completely resistant 
to doxorubicin, were very responsive to the cytotoxic drug 
(doxorubicin) when it was administered in combination 
Figure 4: Efflux pump function assay. TNBC cells treated with MIA-602 have significantly reduced efflux pump function compared 
to controls as evidenced by the retention of fluorescent dye. Vertical bars indicate ± SEM, n=9 samples, * P < 0.01 vs. control.
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with MIA-602. Real-time RT-PCR analysis of the MX-1 
tumors indicates that the expression of genes involved 
in drug resistance was reduced by treatment with MIA-
602. The genes MDR1 and NANOG, both involved in the 
regulation and expression of efflux pump mechanisms, 
were significantly suppressed. Additionally, cells treated 
with MIA-602 showed a significant increases in Calcein 
dye retention, indicating that efflux pump function was 
reduced. These results illustrate the ability of GHRH 
antagonists to not only inhibit the growth of tumors, 
but also to enhance the effectiveness of other drugs by 
reducing resistance. 
Several reports have detailed the effects of treatment 
with GHRH antagonists on the growth of breast cancers.
[6, 20, 57, 58] The study presented herein illustrates 
the role of GHRH signaling in the regulation of drug 
resistance in TNBC. Our results also demonstrate the 
ability of a GHRH antagonist, MIA-602, to be a potential 
new treatment for drug resistant cancers. Our data suggest 
that changes in the expression of genes associated with 
drug resistance and cancer cell “stemness”, induced by 
treatment with MIA-602, lead to a significant reduction 
in the efflux capacity of drug resistant cells. This results 
in the accumulation of the cytotoxic drug in cells with 
disabled efflux mechanisms and reduces resistance. This 
study illustrates the potential benefits of using GHRH 
antagonists for the treatment of cancers that are highly 
resistant to cytotoxic agents such as doxorubicin. 
METHODS
Drugs and Chemicals
The GHRH antagonistic analog, MIA-602, was 
synthesized in our laboratory as previously described.
[7, 59] For daily subcutaneous injection, MIA-602 was 
dissolved in a 0.1% / 10% DMSO/propylene glycol 
solution. Doxorubicin was dissolved in a sterile solution of 
5% mannitol for weekly intravenous injection. For in-vitro 
studies, both MIA-602 and doxorubicin were dissolved 
in DMSO to a concentration of 10mM and 2.5mM, 
respectively. The DMSO stock solutions were diluted with 
culture media keeping the final concentration of DMSO to 
less than 0.01%.
Animals
Female nude mice (Harlan Laboratories) between 
10 and 11 weeks of age (20g body weight) were housed 
in a climate-controlled environment with a 12-h light/
dark cycle and were fed standard laboratory diet with 
water ad libitum. Body weights were determined weekly. 
All animals remained healthy throughout the experiment. 
Animal care was in accordance with institutional 
guidelines and complied with National Institutes of Health 
policy.
Cell Culture
Cultures of the human triple negative breast cancer 
cell line, HCC1806, were maintained in RPMI 1640 
medium supplemented with 10% FBS. Flask cultures were 
kept in a humidified incubator in a 5% CO2 atmosphere at 
37oC. Growth medium was replaced every 72 hours for 
two weeks. Cells were collected using 0.05% trypsin and 
incubating at 37oC for 3 minutes. Trypsin was inactivated 
with an equal volume of FBS containing medium and the 
cells were collected by centrifugation at 1000 x g for 10 
minutes.
Study Design
Donor animals were xenografted with 105 cells and 
tumors were allowed to grow for 4 weeks. The tumors 
were collected from euthanized animals and cut into 
approximately 5 mg fragments. Fragments were rinsed 
with sterile PBS and xenografted subcutaneously into 
both flanks of each animal. Tumors were allowed to grow 
to a mean volume of 75-100 mm3 prior to administration 
of the initial treatment. Animals were randomly assigned 
to one of four experimental groups. The control group 
remained untreated and the treated groups received daily 
subcutaneous injection of MIA-602 (5µg/day) and/or 
weekly intravenous (jugular) injections of doxorubicin 
(2.5nmol/kg/wk). Animals were treated for up to 5 weeks 
and tumor volume (mm3) = (length x width x height x 
0.5236) and body weight were assessed weekly. Tumor 
inhibition (%) was calculated according to the following 
formula: [(final volume control - initial volume control) 
- (final volume treated - initial volume treated)]/(final 
volume control-initial volume control) x 100 [60]. All 
animals were euthanized by cervical dislocation upon 
study completion and tumors collected postmortem.
RNA Isolation
Excised tumors were immediately cut into 
approximately 25 mg pieces and submerged in RNAlater 
(Ambion) stabilization solution. After an overnight 
incubation at 4oC, for thorough stabilization, samples 
were homogenized in lysis buffer and total RNA was 
isolated using the GE Illustra RNAspin Isolation Kit (GE 
Healthcare) according to the manufacturer’s protocol. 
Contaminating DNA was eliminated with an on-column 
DNase treatment as part of the isolation procedure. Total 
RNA was quantified and assessed for purity using a 
Nanodrop spectrophotometer (Thermo Scientific).
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SYBR Green-based RT-PCR Primer Design
Gene expression was determined using qRT-PCR. 
All RNA targets were analyzed using custom designed 
oligonucleotide primers designed for use in SYBR green 
based qRT-PCR. The assays were painstakingly designed 
using extremely strict parameters in order to exclude 
non-human (mouse) templates and target regions of low 
energy secondary structures, maximizing both specificity 
and sensitivity. All assays were determined to produce a 
single product which was verified as the human target of 
interest by DNA sequencing.
Transcript specific primers were designed using the 
Beacon Designer software suite (Premiere Biosoft) with 
modified parameters. Primer searches were conducted to 
regions on mRNA sequences, obtained from the NCBI 
database, which were not homologous to the equivalent 
mRNA from mice (Mus musculus). The resulting human-
specific sequences were screened for regions of stable 
secondary structures (∆G < -3.0 Kcal/mol), which were 
excluded from our primer search. Primer searches were 
optimized for reverse transcription at 52oC and fast cycling 
polymerase chain reaction at 57oC. Primer hairpin energy 
was limited to ∆G = -3.0 Kcal/mol and dimer energies 
were limited to ∆G = -4.0 Kcal/mol. Dimers including the 
last 3 bases of the 3’ end of the primer were limited to 
∆G = -2.0 Kcal/mol. Primers were designed to result in 
amplicons of 75-200 bp in length. Primer pairs that were 
less than 98% efficient were excluded. All primers used 
produce a single product of predictable and reproducible 
melting temperature (Tm). All primers were optimized and 
verified by sequencing the corresponding amplicons.
Real-time Quantitative Reverse-Transcription 
Polymerase Chain Reaction (qRT-PCR)
Gene expression analysis was conducted using one-
step qRT-PCR with SYBR green chemistry. This method 
conducts the reverse transcription reaction and PCR in a 
single tube format from 20ng total RNA template. The 
production of the PCR amplified gene product is monitored 
using the fluorescence resulting from the binding of SYBR 
green to the double stranded DNA amplicons. Reactions 
were conducted in a CFX96 Real-Time System using the 
One-Step SYBR Green qRT-PCR reaction kit (Bio-Rad). 
Reactions were conducted in triplicate and normalized to 
three internal standard genes using the δδCt method.[61]
Efflux Pump Function Assay
Multidrug resistance of MX-1 and HCC-1806 cells 
was measured by calcein retention assay according to the 
manufacturer`s instructions (Cayman Chemical) [62]. 
Briefly, cells were seeded onto 96-well plates to 20,000 
cells/well density. Two days later, culture medium was 
replaced with Optimem (Life Technologies) containing 
0.1 µM- 5 µM MIA-602 for 4 hours. Calcein-AM and 
Hoechst were added at the end of the treatment for 10 
minutes and the developed fluorescence was measured 
in assay buffer in a Victor3 plate reader (Hoechst at 
excitation and emission wavelengths of 355 nm and 465 
nm, respectively and calcein at excitation and emission 
wavelengths of 485 nm and 535 nm, respectively). Values 
of calcein retention (efflux function) were normalized to 
Hoechst nuclear staining (viable cell density). 
Statistical Analysis
Prism 5 software (Graphpad Software, Inc.) was 
used for statistical evaluation of the data. Results are 
expressed as means ± SEM. One-way ANOVA followed 
by Bonferroni t test or a two-tailed Student’s t test was 
used where appropriate, and significance was accepted at 
P < 0.05.
 ACKNOWLEDGEMENTS
This material is based upon work supported in part 
by the Department of Veterans Affairs, Veterans Health 
Administration, Office of Research and Development of 
the Miami VA Healthcare System; by the Department of 
Medicine, Sylvester Comprehensive Cancer Center; and 
Division of Hematology/Oncology of the Miller Medical 
School, Miller School of Medicine, University of Miami; 
by the South Florida Veterans Affairs Foundation for 
Research and Education (all to A.V.S.). P.P. was supported 
by a stipend program of the Department of Medicine, 
Dresden, Germany and by the Helmholtz Alliance Imaging 
and Curing Environmental Metabolic Diseases through 
the Initiative and Networking Fund of the Helmholtz 
Association. F.G.R. received support from the Urology 
Care Foundation Research Scholars Program and the AUA 
Southeastern Section. The contents of this work do not 
represent the views of the Department of Veterans Affairs 
or the United States Government.
RP: Study design, animal protocol approval 
request (IACUC), animal studies, genetic analysis, data 
acquisition and analysis, manuscript preparation and 
revision. AS: Study design, peptide analog design, data 
analysis, manuscript preparation and revision. RC: 
Peptide analog design and synthesis and manuscript 
preparation. PP: Animal studies, efflux pump assay, and 
manuscript preparation. WS: Peptide analog purification, 
injectable drug formulation, and manuscript preparation. 
RR: Biosafety protocol approval request, cell culture, data 
analysis, and manuscript preparation. FR: Animal studies, 
data analysis, and manuscript preparation and revision.
Oncoscience671www.impactjournals.com/oncoscience
REFERENCES
1. CDC. (2010). Centers for Disease Control and Prevention: 
US Incidence of Breast Cancer.
2. Buchholz S, Seitz S, Schally AV, Engel JB, Rick FG, 
Szalontay L, Hohla F, Krishan A, Papadia A, Gaiser T, 
Brockhoff G, Ortmann O, Diedrich K and Koster F. Triple-
negative breast cancers express receptors for luteinizing 
hormone-releasing hormone (LHRH) and respond to LHRH 
antagonist cetrorelix with growth inhibition. Int J Oncol. 
2009; 35(4):789-796.
3. Dawson SJ, Provenzano E and Caldas C. Triple negative 
breast cancers: clinical and prognostic implications. Eur J 
Cancer. 2009; 45 Suppl 1(19775602):27-40.
4. Seitz S, Buchholz S, Schally AV, Jayakumar AR, Weber 
F, Papadia A, Rick FG, Szalontay L, Treszl A, Koster F, 
Ortmann O and Hohla F. Targeting triple-negative breast 
cancer through the somatostatin receptor with the new 
cytotoxic somatostatin analogue AN-162 [AEZS-124]. 
Anticancer Drugs. 2013; 24(2):150-157.
5. Bartsch R, Ziebermayr R, Zielinski CC and Steger GG. 
Triple-negative breast cancer. Wien Med Wochenschr. 2010; 
160(20473728):174-181.
6. Schally AV, Varga JL and Engel JB. Antagonists of growth-
hormone-releasing hormone: an emerging new therapy for 
cancer. Nat Clin Pract Endocrinol Metab. 2008; 4(1):33-43.
7. Varga JL, Schally AV, Horvath JE, Kovacs M, Halmos G, 
Groot K, Toller GL, Rekasi Z and Zarandi M. Increased 
activity of antagonists of growth hormone-releasing 
hormone substituted at positions 8, 9, and 10. Proc Natl 
Acad Sci U S A. 2004; 101(14755056):1708-1713.
8. Szereday Z, Schally AV, Varga JL, Kanashiro CA, Hebert 
F, Armatis P, Groot K, Szepeshazi K, Halmos G and Busto 
R. Antagonists of growth hormone-releasing hormone 
inhibit the proliferation of experimental non-small cell lung 
carcinoma. Cancer Res. 2003; 63(14633721):7913-7919.
9. Weiss-Messer E, Merom O, Adi A, Karry R, Bidosee M, 
Ber R, Kaploun A, Stein A and Barkey RJ. Growth hormone 
(GH) receptors in prostate cancer: gene expression in human 
tissues and cell lines and characterization, GH signaling and 
androgen receptor regulation in LNCaP cells. Molecular and 
Cellular Endocrinology. 2004; 220(1-2):109-123.
10. Rick FG, Schally AV, Block NL, Nadji M, Szepeshazi K, 
Zarandi M, Vidaurre I, Perez R, Halmos G and Szalontay 
L. Antagonists of growth hormone-releasing hormone 
(GHRH) reduce prostate size in experimental benign 
prostatic hyperplasia. Proc Natl Acad Sci U S A. 2011; 
108(9):3755-3760.
11. Jaszberenyi M, Rick FG, Szalontay L, Block NL, Zarandi 
M, Cai RZ and Schally AV. Beneficial effects of novel 
antagonists of GHRH in different models of Alzheimer’s 
disease. Aging. 2012; 4(11):755-767.
12. Lucas R, Sridhar S, Rick FG, Gorshkov B, Umapathy NS, 
Yang G, Oseghale A, Verin AD, Chakraborty T, Matthay 
MA, Zemskov EA, White R, Block NL and Schally AV. 
Agonist of growth hormone-releasing hormone reduces 
pneumolysin-induced pulmonary permeability edema. Proc 
Natl Acad Sci U S A. 2012; 109(6):2084-2089.
13. Rick FG, Szalontay L, Schally AV, Block NL, Nadji M, 
Szepeshazi K, Vidaurre I, Zarandi M, Kovacs M and 
Rekasi Z. Combining growth hormone-releasing hormone 
antagonist with luteinizing hormone-releasing hormone 
antagonist greatly augments benign prostatic hyperplasia 
shrinkage. J Urol. 2012; 187(4):1498-1504.
14. Rick FG, Schally AV, Block NL, Abi-Chaker A, Krishan 
A and Szalontay L. Mechanisms of synergism between 
antagonists of growth hormone-releasing hormone and 
antagonists of luteinizing hormone-releasing hormone 
in shrinking experimental benign prostatic hyperplasia. 
Prostate. 2013; 73(8):873-883.
15. Rick FG, Saadat SH, Szalontay L, Block NL, Kazzazi 
A, Djavan B and Schally AV. Hormonal manipulation 
of benign prostatic hyperplasia. Curr Opin Urol. 2013; 
23(1):17-24.
16. Czikora I, Sridhar S, Gorshkov B, Kasa A, Alieva I, 
Gonzales J, Potapenko O, Umapathy NS, Verin AD, 
Pillich H, Rick FG, Block NL, Chakraborty T, Matthay 
MA, Schally AV and Lucas R. Protective effect of Growth 
Hormone-Releasing Hormone agonist in bacterial toxin-
induced pulmonary barrier dysfunction. Frontiers in 
Physiology. 2014; 5.
17. Havt A, Schally AV, Halmos G, Varga JL, Toller GL, 
Horvath JE, Szepeshazi K, Koster F, Kovitz K, Groot 
K, Zarandi M and Kanashiro CA. The expression of the 
pituitary growth hormone-releasing hormone receptor and 
its splice variants in normal and neoplastic human tissues. 
Proc Natl Acad Sci U S A. 2005; 102(16299104):17424-
17429.
18. Heinrich E, Schally AV, Buchholz S, Rick FG, Halmos 
G, Mile M, Groot K, Hohla F, Zarandi M and Varga JL. 
Dose-dependent growth inhibition in vivo of PC-3 prostate 
cancer with a reduction in tumoral growth factors after 
therapy with GHRH antagonist MZ-J-7-138. Prostate. 2008; 
68(16):1763-1772.
19. Kovacs M, Schally AV, Hohla F, Rick FG, Pozsgai E, 
Szalontay L, Varga JL and Zarandi M. A correlation of 
endocrine and anticancer effects of some antagonists of 
GHRH. Peptides. 2010; 31(10):1839-1846.
20. Pozsgai E, Schally AV, Hocsak E, Zarandi M, Rick F 
and Bellyei S. The effect of a novel antagonist of growth 
hormone releasing hormone on cell proliferation and on the 
key cell signaling pathways in nine different breast cancer 
cell lines. Int J Oncol. 2011; 39(4):1025-1032.
21. Papadia A, Schally AV, Halmos G, Varga JL, Seitz S, 
Buchholz S, Rick F, Zarandi M, Bellyei S, Treszl A, 
Szalontay L and Lucci JA. Growth hormone-releasing 
hormone antagonists inhibit growth of human ovarian 
cancer. Horm Metab Res. 2011; 43(11):816-820.
22. Abdel-Wahab M, Schally AV, Rick FG, Szalontay L, Block 
NL, Jorda M, Mahmoud O, Markoe A, Shi Y-F, Reiner T, 
Oncoscience672www.impactjournals.com/oncoscience
Zarandi M and Duncan R. Antagonists of growth hormone 
releasing hormone (GHRH) given before whole body 
radiation lead to modulation of radiation response and 
organ-specific changes in the expression of angiogenesis. J 
Radiat Oncol. 2012; 1(4):389-396.
23. Rick FG, Schally AV, Szalontay L, Block NL, Szepeshazi 
K, Nadji M, Zarandi M, Hohla F, Buchholz S and Seitz S. 
Antagonists of growth hormone-releasing hormone inhibit 
growth of androgen-independent prostate cancer through 
inactivation of ERK and Akt kinases. Proc Natl Acad Sci U 
S A. 2012; 109(5):1655-1660.
24. Rick FG, Seitz S, Schally AV, Szalontay L, Krishan A, Datz 
C, Stadlmayr A, Buchholz S, Block NL and Hohla F. GHRH 
antagonist when combined with cytotoxic agents induces 
S-phase arrest and additive growth inhibition of human 
colon cancer. Cell Cycle. 2012; 11(22):4203-4210.
25. Stangelberger A, Schally AV, Rick FG, Varga JL, Baker B, 
Zarandi M and Halmos G. Inhibitory effects of antagonists 
of growth hormone releasing hormone on experimental 
prostate cancers are associated with upregulation of wild-
type p53 and decrease in p21 and mutant p53 proteins. 
Prostate. 2012; 72(5):555-565.
26. Jaszberenyi M, Schally AV, Block NL, Zarandi M, Cai 
RZ, Vidaurre I, Szalontay L, Jayakumar AR and Rick 
FG. Suppression of the proliferation of human U-87 MG 
glioblastoma cells by new antagonists of growth hormone-
releasing hormone in vivo and in vitro. Targeted oncology. 
2013; 8(4):281-290.
27. Seitz S, Rick FG, Schally AV, Treszl A, Hohla F, Szalontay 
L, Zarandi M, Ortmann O, Engel JB and Buchholz S. 
Combination of GHRH antagonists and docetaxel shows 
experimental effectiveness for the treatment of triple-
negative breast cancers. Oncol Rep. 2013; 30(1):413-418.
28. Szalontay L, Schally AV, Popovics P, Vidaurre I, Krishan A, 
Zarandi M, Cai RZ, Klukovits A, Block NL and Rick FG. 
Novel GHRH antagonists suppress the growth of human 
malignant melanoma by restoring nuclear p27 function. Cell 
Cycle. 2014.
29. Kiaris H, Schally AV, Varga JL, Groot K and Armatis P. 
Growth hormone-releasing hormone: an autocrine growth 
factor for small cell lung carcinoma. Proc Natl Acad Sci U 
S A. 1999; 96(26):14894-14898.
30. Schally AV. New approaches to the therapy of various 
tumors based on peptide analogues. Horm Metab Res. 2008; 
40(5):315-322.
31. Fahrenholtz CD, Rick FG, Garcia MI, Zarandi M, Cai 
RZ, Block NL, Schally AV and Burnstein KL. Preclinical 
efficacy of growth hormone-releasing hormone antagonists 
for androgen-dependent and castration-resistant human 
prostate cancer. Proc Natl Acad Sci U S A. 2014; 
111(3):1084-1089.
32. Siriwardana G, Bradford A, Coy D and Zeitler P. Autocrine/
paracrine regulation of breast cancer cell proliferation by 
growth hormone releasing hormone via Ras, Raf, and 
mitogen-activated protein kinase. Mol Endocrinol. 2006; 
20(9):2010-2019.
33. Rekasi Z, Czompoly T, Schally AV and Halmos G. Isolation 
and sequencing of cDNAs for splice variants of growth 
hormone-releasing hormone receptors from human cancers. 
Proc Natl Acad Sci U S A. 2000; 97(19):10561-10566.
34. Csernus VJ, Schally AV, Kiaris H and Armatis P. Inhibition 
of growth, production of insulin-like growth factor-II (IGF-
II), and expression of IGF-II mRNA of human cancer cell 
lines by antagonistic analogs of growth hormone-releasing 
hormone in vitro. Proc Natl Acad Sci U S A. 1999; 
96(10077643):3098-3103.
35. Kiaris H, Chatzistamou I, Schally AV, Halmos G, Varga 
JL, Koutselini H and Kalofoutis A. Ligand-dependent and 
-independent effects of splice variant 1 of growth hormone-
releasing hormone receptor. Proc Natl Acad Sci U S A. 
2003; 100(16):9512-9517.
36. Perez RS, AV; Vidaurre, I; Rincon, R; Block, NL; Rick, 
FG. Antagonists of growth hormone-releasing hormone 
suppress in vivo tumor growth and gene expression in triple 
negative breast cancers. Oncotarget. 2012; 3(9):988-997.
37. Gerger A, Renner W, Langsenlehner T, Hofmann G, 
Knechtel G, Szkandera J, Samonigg H, Krippl P and 
Langsenlehner U. Association of interleukin-10 gene 
variation with breast cancer prognosis. Breast Cancer Res 
Treat. 2010; 119(19437115):701-705.
38. Tawara K, Oxford JT and Jorcyk CL. Clinical significance 
of interleukin (IL)-6 in cancer metastasis to bone: 
potential of anti-IL-6 therapies. Cancer Manag Res. 2011; 
3(21625400):177-189.
39. Zhao X, Sun X, Gao F, Luo J and Sun Z. Effects of 
ulinastatin and docataxel on breast tumor growth and 
expression of IL-6, IL-8, and TNF-alpha. J Exp Clin Cancer 
Res. 2011; 30(1):22.
40. Szepeshazi K, Schally AV, Block NL, Halmos G, Nadji 
M, Szalontay L, Vidaurre I, Abi-Chaker A and Rick FG. 
Powerful inhibition of experimental human pancreatic 
cancers by receptor targeted cytotoxic LH-RH analog 
AEZS-108. Oncotarget. 2013; 4(5):751-760.
41. Schally AV, Varga JL and Engel JB. Antagonists of growth-
hormone-releasing hormone: an emerging new therapy 
for cancer. Nature Clinical Practice Endocrinology &#38; 
Metabolism. 2008; 4(1):33-43.
42. Khorram O, Garthwaite M, Grosen E and Golos T. Human 
uterine and ovarian expression of growth hormone-
releasing hormone messenger RNA in benign and 
malignant gynecologic conditions. Fertil Steril. 2001; 
75(11163834):174-179.
43. Hohla F, Schally AV, Szepeshazi K, Varga JL, Buchholz S, 
Koster F, Heinrich E, Halmos G, Rick FG, Kannadka C, 
Datz C and Kanashiro CA. Synergistic inhibition of growth 
of lung carcinomas by antagonists of growth hormone-
releasing hormone in combination with docetaxel. Proc Natl 
Acad Sci U S A. 2006; 103(16983095):14513-14518.
44. Kanashiro CA, Schally AV, Groot K, Armatis P, 
Oncoscience673www.impactjournals.com/oncoscience
Bernardino ALF and Varga JL. Inhibition of mutant 
p53 expression and growth of DMS-153 small cell lung 
carcinoma by antagonists of growth hormone-releasing 
hormone and bombesin. Proc Natl Acad Sci U S A. 2003; 
100(14660794):15836-15841.
45. Maitland NJ and Collins AT. Prostate Cancer Stem Cells: 
A New Target for Therapy. Journal of Clinical Oncology. 
2008; 26(17):2862-2870.
46. Pradhan M, Bembinster LA, Baumgarten SC and Frasor 
J. Proinflammatory cytokines enhance estrogen-dependent 
expression of the multidrug transporter gene ABCG2 
through estrogen receptor and NF{kappa}B cooperativity 
at adjacent response elements. J Biol Chem. 2010; 
285(41):31100-31106.
47. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, 
Ramirez N, Oberyszyn TM and Hall BM. Interleukin-6 
induces an epithelial-mesenchymal transition phenotype 
in human breast cancer cells. Oncogene. 2009; 
28(19581928):2940-2947.
48. Iliopoulos D, Hirsch HA, Wang G and Struhl K. Inducible 
formation of breast cancer stem cells and their dynamic 
equilibrium with non-stem cancer cells via IL6 secretion. 
Proc Natl Acad Sci U S A. 2011; 108(21220315):1397-
1402.
49. Guo W, Lasky JL, Chang C-J, Mosessian S, Lewis X, Xiao 
Y, Yeh JE, Chen JY, Iruela-Arispe ML, Varella-Garcia M 
and Wu H. Multi-genetic events collaboratively contribute 
to Pten-null leukaemia stem-cell formation. Nature. 2008; 
453(18463637):529-533.
50. Lopez-Novoa JM and Nieto MA. Inflammation and EMT: 
an alliance towards organ fibrosis and cancer progression. 
EMBO Mol Med. 2009; 1(6-7):303-314.
51. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements 
JA, Williams ED and Thompson EW. Epithelial--
mesenchymal and mesenchymal--epithelial transitions in 
carcinoma progression. J Cell Physiol. 2007; 213(2):374-
383.
52. Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-
Trejo L, Leibovich-Rivkin T, Weitzenfeld P, Meshel T, 
Shabtai E, Gutman M and Ben-Baruch A. Inflammatory 
mediators in breast cancer: Coordinated expression of TNFα 
& IL-1β with CCL2 & CCL5 and effects on epithelial-to-
mesenchymal transition. BMC Cancer. 2011; 11(1):130.
53. Rick FG, Schally AV, Block NL, Nadji M, Szepeshazi K, 
Zarandi M, Vidaurre I, Perez R, Halmos G and Szalontay 
L. Antagonists of growth hormone-releasing hormone 
(GHRH) reduce prostate size in experimental benign 
prostatic hyperplasia. Proc Natl Acad Sci U S A. 2011; 
108(21321192):3755-3760.
54. Hohla F, Winder T, Greil R, Rick FG, Block NL and Schally 
AV. Targeted therapy in advanced metastatic colorectal 
cancer: Current concepts and perspectives. World journal 
of gastroenterology : WJG. 2014; 20(20):6102-6112.
55. Hohla F, Buchholz S, Schally AV, Seitz S, Rick FG, 
Szalontay L, Varga JL, Zarandi M, Halmos G, Vidaurre 
I, Krishan A, Kurtoglu M, Chandna S, Aigner E and Datz 
C. GHRH antagonist causes DNA damage leading to p21 
mediated cell cycle arrest and apoptosis in human colon 
cancer cells. Cell Cycle. 2009; 8(19):3149-3156.
56. Rick FG, Abi-Chaker A, Szalontay L, Perez R, Jaszberenyi 
M, Jayakumar AR, Shamaladevi N, Szepeshazi K, Vidaurre 
I, Halmos G, Krishan A, Block NL and Schally AV. 
Shrinkage of experimental benign prostatic hyperplasia 
and reduction of prostatic cell volume by a gastrin-releasing 
peptide antagonist. Proc Natl Acad Sci U S A. 2013; 
110(7):2617-2622.
57. Seitz S, Hohla F, Schally AV, Moder A, Engel JB, Horn F, 
Varga J, Zarandi M, Ortmann O, Koster F and Buchholz S. 
Inhibition of estrogen receptor positive and negative breast 
cancer cell lines with a growth hormone-releasing hormone 
antagonist. Oncol Rep. 2008; 20(5):1289-1294.
58. Koster F, Engel JB, Schally AV, Honig A, Schroer A, 
Seitz S, Hohla F, Ortmann O, Diedrich K and Buchholz 
S. Triple-negative breast cancers express receptors for 
growth hormone-releasing hormone (GHRH) and respond 
to GHRH antagonists with growth inhibition. Breast Cancer 
Res Treat. 2009; 116(2):273-279.
59. Zarandi M, Horvath JE, Halmos G, Pinski J, Nagy A, Groot 
K, Rekasi Z and Schally AV. Synthesis and biological 
activities of highly potent antagonists of growth hormone-
releasing hormone. Proc Natl Acad Sci U S A. 1994; 
91(25):12298-12302.
60. Rick FG, Buchholz S, Schally AV, Szalontay L, Krishan A, 
Datz C, Stadlmayr A, Aigner E, Perez R, Seitz S, Block 
NL and Hohla F. Combination of gastrin-releasing peptide 
antagonist with cytotoxic agents produces synergistic 
inhibition of growth of human experimental colon cancers. 
Cell Cycle. 2012; 11(13):2518-2525.
61. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy 
N, De Paepe A and Speleman F. Accurate normalization of 
real-time quantitative RT-PCR data by geometric averaging 
of multiple internal control genes. Genome Biol. 2002; 
3(7):RESEARCH0034.
62. Szepeshazi K, Schally AV, Keller G, Block NL, Benten 
D, Halmos G, Szalontay L, Vidaurre I, Jaszberenyi M and 
Rick FG. Receptor-targeted therapy of human experimental 
urinary bladder cancers with cytotoxic LH-RH analog AN-
152 [AEZS- 108]. Oncotarget. 2012; 3(7):686-699.
